A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs RX 0201 (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 26 Sep 2017 Planned number of patients changed from 39 to 23.
- 26 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.
- 26 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History